Intrinsic value of Neos Therapeutics - NEOS

Previous Close

$2.13

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$2.13

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of NEOS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  40
  62
  92
  134
  189
  260
  349
  459
  590
  746
  926
  1,132
  1,364
  1,623
  1,909
  2,220
  2,558
  2,920
  3,307
  3,718
  4,153
  4,611
  5,091
  5,593
  6,119
  6,666
  7,236
  7,829
  8,446
  9,087
Variable operating expenses, $m
  374
  576
  861
  1,249
  1,761
  2,421
  3,249
  4,266
  5,488
  6,932
  8,606
  10,521
  12,682
  15,089
  17,742
  20,638
  23,773
  27,142
  30,740
  34,561
  38,600
  42,853
  47,317
  51,989
  56,869
  61,958
  67,258
  72,772
  78,505
  84,464
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  374
  576
  861
  1,249
  1,761
  2,421
  3,249
  4,266
  5,488
  6,932
  8,606
  10,521
  12,682
  15,089
  17,742
  20,638
  23,773
  27,142
  30,740
  34,561
  38,600
  42,853
  47,317
  51,989
  56,869
  61,958
  67,258
  72,772
  78,505
  84,464
Operating income, $m
  -334
  -515
  -769
  -1,115
  -1,572
  -2,161
  -2,900
  -3,807
  -4,898
  -6,186
  -7,680
  -9,389
  -11,317
  -13,465
  -15,833
  -18,417
  -21,215
  -24,222
  -27,433
  -30,843
  -34,447
  -38,243
  -42,226
  -46,396
  -50,751
  -55,292
  -60,022
  -64,943
  -70,059
  -75,377
EBITDA, $m
  -329
  -508
  -760
  -1,102
  -1,555
  -2,138
  -2,870
  -3,769
  -4,849
  -6,125
  -7,606
  -9,299
  -11,209
  -13,336
  -15,681
  -18,240
  -21,011
  -23,989
  -27,169
  -30,546
  -34,116
  -37,875
  -41,820
  -45,950
  -50,263
  -54,761
  -59,445
  -64,318
  -69,385
  -74,652
Interest expense (income), $m
  3
  10
  15
  26
  41
  63
  91
  127
  172
  228
  295
  374
  466
  570
  689
  821
  966
  1,124
  1,296
  1,481
  1,678
  1,887
  2,108
  2,341
  2,585
  2,841
  3,108
  3,387
  3,677
  3,979
  4,293
Earnings before tax, $m
  -343
  -529
  -795
  -1,156
  -1,635
  -2,251
  -3,026
  -3,979
  -5,126
  -6,481
  -8,054
  -9,855
  -11,888
  -14,154
  -16,654
  -19,383
  -22,340
  -25,518
  -28,913
  -32,520
  -36,334
  -40,351
  -44,567
  -48,981
  -53,592
  -58,401
  -63,409
  -68,620
  -74,038
  -79,670
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -343
  -529
  -795
  -1,156
  -1,635
  -2,251
  -3,026
  -3,979
  -5,126
  -6,481
  -8,054
  -9,855
  -11,888
  -14,154
  -16,654
  -19,383
  -22,340
  -25,518
  -28,913
  -32,520
  -36,334
  -40,351
  -44,567
  -48,981
  -53,592
  -58,401
  -63,409
  -68,620
  -74,038
  -79,670

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  138
  213
  319
  463
  653
  898
  1,205
  1,582
  2,036
  2,571
  3,193
  3,903
  4,705
  5,598
  6,582
  7,657
  8,820
  10,070
  11,404
  12,822
  14,320
  15,898
  17,554
  19,288
  21,098
  22,986
  24,952
  26,998
  29,125
  31,336
Adjusted assets (=assets-cash), $m
  138
  213
  319
  463
  653
  898
  1,205
  1,582
  2,036
  2,571
  3,193
  3,903
  4,705
  5,598
  6,582
  7,657
  8,820
  10,070
  11,404
  12,822
  14,320
  15,898
  17,554
  19,288
  21,098
  22,986
  24,952
  26,998
  29,125
  31,336
Revenue / Adjusted assets
  0.290
  0.291
  0.288
  0.289
  0.289
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
  0.290
Average production assets, $m
  26
  40
  60
  87
  122
  168
  226
  296
  381
  482
  598
  731
  881
  1,049
  1,233
  1,434
  1,652
  1,886
  2,137
  2,402
  2,683
  2,978
  3,289
  3,613
  3,953
  4,306
  4,675
  5,058
  5,456
  5,870
Working capital, $m
  -5
  -8
  -13
  -18
  -26
  -36
  -48
  -63
  -81
  -102
  -127
  -155
  -187
  -222
  -262
  -304
  -350
  -400
  -453
  -509
  -569
  -632
  -697
  -766
  -838
  -913
  -991
  -1,073
  -1,157
  -1,245
Total debt, $m
  90
  158
  253
  382
  553
  773
  1,050
  1,389
  1,798
  2,280
  2,839
  3,479
  4,200
  5,004
  5,889
  6,856
  7,903
  9,028
  10,230
  11,505
  12,854
  14,274
  15,764
  17,325
  18,954
  20,653
  22,423
  24,264
  26,178
  28,168
Total liabilities, $m
  124
  192
  287
  416
  588
  808
  1,084
  1,424
  1,832
  2,314
  2,873
  3,513
  4,234
  5,038
  5,924
  6,891
  7,938
  9,063
  10,264
  11,540
  12,888
  14,308
  15,799
  17,359
  18,988
  20,688
  22,457
  24,298
  26,213
  28,202
Total equity, $m
  14
  21
  32
  46
  65
  90
  120
  158
  204
  257
  319
  390
  470
  560
  658
  766
  882
  1,007
  1,140
  1,282
  1,432
  1,590
  1,755
  1,929
  2,110
  2,299
  2,495
  2,700
  2,913
  3,134
Total liabilities and equity, $m
  138
  213
  319
  462
  653
  898
  1,204
  1,582
  2,036
  2,571
  3,192
  3,903
  4,704
  5,598
  6,582
  7,657
  8,820
  10,070
  11,404
  12,822
  14,320
  15,898
  17,554
  19,288
  21,098
  22,987
  24,952
  26,998
  29,126
  31,336
Debt-to-equity ratio
  6.510
  7.390
  7.920
  8.260
  8.470
  8.620
  8.710
  8.780
  8.830
  8.870
  8.890
  8.910
  8.930
  8.940
  8.950
  8.960
  8.960
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.980
  8.990
  8.990
  8.990
  8.990
  8.990
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -343
  -529
  -795
  -1,156
  -1,635
  -2,251
  -3,026
  -3,979
  -5,126
  -6,481
  -8,054
  -9,855
  -11,888
  -14,154
  -16,654
  -19,383
  -22,340
  -25,518
  -28,913
  -32,520
  -36,334
  -40,351
  -44,567
  -48,981
  -53,592
  -58,401
  -63,409
  -68,620
  -74,038
  -79,670
Depreciation, amort., depletion, $m
  5
  7
  9
  12
  17
  22
  29
  38
  49
  61
  74
  90
  109
  129
  152
  177
  204
  233
  264
  297
  331
  368
  406
  446
  488
  532
  577
  624
  674
  725
Funds from operations, $m
  -339
  -523
  -786
  -1,144
  -1,618
  -2,229
  -2,997
  -3,941
  -5,077
  -6,420
  -7,980
  -9,765
  -11,779
  -14,025
  -16,501
  -19,206
  -22,136
  -25,285
  -28,650
  -32,224
  -36,003
  -39,983
  -44,161
  -48,535
  -53,104
  -57,869
  -62,832
  -67,995
  -73,365
  -78,945
Change in working capital, $m
  -2
  -3
  -4
  -6
  -8
  -10
  -12
  -15
  -18
  -21
  -25
  -28
  -32
  -35
  -39
  -43
  -46
  -50
  -53
  -56
  -60
  -63
  -66
  -69
  -72
  -75
  -78
  -81
  -85
  -88
Cash from operations, $m
  -337
  -520
  -781
  -1,138
  -1,610
  -2,219
  -2,985
  -3,926
  -5,059
  -6,399
  -7,955
  -9,736
  -11,747
  -13,989
  -16,462
  -19,164
  -22,090
  -25,236
  -28,597
  -32,167
  -35,943
  -39,920
  -44,095
  -48,466
  -53,032
  -57,794
  -62,754
  -67,914
  -73,280
  -78,857
Maintenance CAPEX, $m
  -2
  -3
  -5
  -7
  -11
  -15
  -21
  -28
  -37
  -47
  -59
  -74
  -90
  -109
  -129
  -152
  -177
  -204
  -233
  -264
  -297
  -331
  -368
  -406
  -446
  -488
  -532
  -577
  -624
  -674
New CAPEX, $m
  -10
  -14
  -20
  -27
  -36
  -46
  -58
  -71
  -85
  -100
  -116
  -133
  -150
  -167
  -184
  -201
  -218
  -234
  -250
  -266
  -281
  -296
  -310
  -325
  -339
  -354
  -368
  -383
  -398
  -414
Cash from investing activities, $m
  -12
  -17
  -25
  -34
  -47
  -61
  -79
  -99
  -122
  -147
  -175
  -207
  -240
  -276
  -313
  -353
  -395
  -438
  -483
  -530
  -578
  -627
  -678
  -731
  -785
  -842
  -900
  -960
  -1,022
  -1,088
Free cash flow, $m
  -348
  -537
  -806
  -1,172
  -1,657
  -2,280
  -3,063
  -4,024
  -5,181
  -6,546
  -8,131
  -9,943
  -11,988
  -14,265
  -16,776
  -19,517
  -22,485
  -25,674
  -29,080
  -32,697
  -36,521
  -40,547
  -44,773
  -49,197
  -53,817
  -58,636
  -63,654
  -68,874
  -74,303
  -79,945
Issuance/(repayment) of debt, $m
  30
  68
  95
  129
  171
  220
  276
  339
  408
  482
  559
  640
  721
  804
  886
  967
  1,047
  1,125
  1,201
  1,276
  1,349
  1,420
  1,490
  1,560
  1,630
  1,699
  1,770
  1,841
  1,914
  1,990
Issuance/(repurchase) of shares, $m
  365
  537
  805
  1,171
  1,654
  2,276
  3,057
  4,017
  5,171
  6,535
  8,116
  9,926
  11,968
  14,244
  16,752
  19,491
  22,456
  25,643
  29,047
  32,662
  36,484
  40,508
  44,733
  49,154
  53,773
  58,590
  63,606
  68,824
  74,251
  79,891
Cash from financing (excl. dividends), $m  
  395
  605
  900
  1,300
  1,825
  2,496
  3,333
  4,356
  5,579
  7,017
  8,675
  10,566
  12,689
  15,048
  17,638
  20,458
  23,503
  26,768
  30,248
  33,938
  37,833
  41,928
  46,223
  50,714
  55,403
  60,289
  65,376
  70,665
  76,165
  81,881
Total cash flow (excl. dividends), $m
  47
  67
  94
  128
  168
  216
  271
  332
  399
  470
  544
  622
  702
  782
  862
  941
  1,018
  1,094
  1,169
  1,241
  1,312
  1,381
  1,450
  1,518
  1,585
  1,653
  1,721
  1,791
  1,862
  1,936
Retained Cash Flow (-), $m
  -365
  -537
  -805
  -1,171
  -1,654
  -2,276
  -3,057
  -4,017
  -5,171
  -6,535
  -8,116
  -9,926
  -11,968
  -14,244
  -16,752
  -19,491
  -22,456
  -25,643
  -29,047
  -32,662
  -36,484
  -40,508
  -44,733
  -49,154
  -53,773
  -58,590
  -63,606
  -68,824
  -74,251
  -79,891
Prev. year cash balance distribution, $m
  17
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -301
  -469
  -711
  -1,043
  -1,486
  -2,060
  -2,787
  -3,685
  -4,772
  -6,064
  -7,572
  -9,304
  -11,266
  -13,462
  -15,890
  -18,550
  -21,438
  -24,549
  -27,878
  -31,421
  -35,172
  -39,127
  -43,283
  -47,637
  -52,188
  -56,937
  -61,884
  -67,033
  -72,389
  -77,956
Discount rate, %
  6.50
  6.83
  7.17
  7.52
  7.90
  8.30
  8.71
  9.15
  9.60
  10.08
  10.59
  11.12
  11.67
  12.26
  12.87
  13.51
  14.19
  14.90
  15.64
  16.43
  17.25
  18.11
  19.01
  19.96
  20.96
  22.01
  23.11
  24.27
  25.48
  26.75
PV of cash for distribution, $m
  -283
  -411
  -578
  -780
  -1,016
  -1,277
  -1,553
  -1,830
  -2,091
  -2,320
  -2,503
  -2,626
  -2,682
  -2,668
  -2,585
  -2,441
  -2,247
  -2,016
  -1,762
  -1,501
  -1,245
  -1,005
  -790
  -603
  -448
  -323
  -226
  -153
  -100
  -64
Current shareholders' claim on cash, %
  50.0
  7.5
  1.2
  0.2
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

FINANCIAL RATIOS  of  Neos Therapeutics (NEOS)

Valuation Ratios
P/E Ratio -0.4
Price to Sales 3.8
Price to Book -17.1
Price to Tangible Book
Price to Cash Flow -0.5
Price to Free Cash Flow -0.5
Growth Rates
Sales Growth Rate 125%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 300%
Cap. Spend. - 3 Yr. Gr. Rate 14.9%
Financial Strength
Quick Ratio 8
Current Ratio 0.2
LT Debt to Equity -2950%
Total Debt to Equity -3200%
Interest Coverage -27
Management Effectiveness
Return On Assets -78.8%
Ret/ On Assets - 3 Yr. Avg. -51.9%
Return On Total Capital -95.4%
Ret/ On T. Cap. - 3 Yr. Avg. -65.2%
Return On Equity -218.4%
Return On Equity - 3 Yr. Avg. -147.9%
Asset Turnover 0.1
Profitability Ratios
Gross Margin -22.2%
Gross Margin - 3 Yr. Avg. -124.1%
EBITDA Margin -844.4%
EBITDA Margin - 3 Yr. Avg. -1014.8%
Operating Margin -866.7%
Oper. Margin - 3 Yr. Avg. -1105.6%
Pre-Tax Margin -922.2%
Pre-Tax Margin - 3 Yr. Avg. -1265.7%
Net Profit Margin -922.2%
Net Profit Margin - 3 Yr. Avg. -1265.7%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

NEOS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the NEOS stock intrinsic value calculation we used $25.018 million for the last fiscal year's total revenue generated by Neos Therapeutics. The default revenue input number comes from 0001 income statement of Neos Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our NEOS stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 6.5%, whose default value for NEOS is calculated based on our internal credit rating of Neos Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Neos Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of NEOS stock the variable cost ratio is equal to 936%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for NEOS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 16.4% for Neos Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for Neos Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the NEOS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for NEOS are equal to 64.6%.

Life of production assets of 8.1 years is the average useful life of capital assets used in Neos Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for NEOS is equal to -13.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $8.947 million for Neos Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 28.997 million for Neos Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Neos Therapeutics at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
PFE Pfizer 43.21 34.10  hold
JNJ Johnson&Johnso 144.50 176.79  buy
SUPN Supernus Pharm 43.11 53.83  buy
LLY Eli Lilly 112.20 67.15  sell
VRTX Vertex Pharmac 166.67 92.21  sell
INVA Innoviva 16.39 6.21  str.sell

COMPANY NEWS

▶ Neos Therapeutics: 3Q Earnings Snapshot   [07:29AM  Associated Press]
▶ Neos Therapeutics: 2Q Earnings Snapshot   [09:22AM  Associated Press]
▶ Neos Therapeutics to Participate in Two June Conferences   [May-31-18 04:05PM  GlobeNewswire]
▶ Neos Therapeutics: 1Q Earnings Snapshot   [May-09-18 07:15AM  Associated Press]
▶ When Will Neos Therapeutics Inc (NASDAQ:NEOS) Turn A Profit?   [Apr-04-18 02:15PM  Simply Wall St.]
▶ Neos Therapeutics reports 4Q loss   [07:35AM  Associated Press]
▶ Neos Therapeutics reports 3Q loss   [Nov-08-17 09:54AM  Associated Press]
▶ Why Neos Therapeutics Inc (NEOS) Shares Climbed 37% Today   [Oct-26-17 01:34PM  SmarterAnalyst]
▶ 5 of the Best Stocks Under $10 for 2017   [Sep-05-17 12:41PM  Zacks]
▶ 'Date' These Potential Biotech Winners   [Aug-25-17 01:30PM  TheStreet.com]
▶ Neos Therapeutics reports 2Q loss   [Aug-08-17 08:23PM  Associated Press]
▶ Shire wins U.S. approval for long-acting ADHD drug   [Jun-21-17 04:32AM  Reuters]
▶ Shire's long-acting ADHD drug wins U.S. approval   [Jun-20-17 07:19PM  Reuters]
▶ Two Red Hot Biotechs With Big Near-term Catalysts Ahead   [May-28-17 03:20PM  Motley Fool]
▶ Neos Therapeutics reports 1Q loss   [May-09-17 09:39AM  Associated Press]
▶ Neos Therapeutics reports 4Q loss   [07:08AM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.